In animal models of myocardial infarction, MR antagonists limit infarct size when administered either prior to ischemia or just before the onset of reperfusion, and protect against cardiac remodeling, as reviewed by van den Berg et al. [20]. This evidence concerns the gene NR3C2 and ischemia.